drug discovery through enzyme inhibition and …...tested - the first sar studies • 1st example...
TRANSCRIPT
![Page 1: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/1.jpg)
Drug Discovery through Enzyme Inhibition and Inactivation
![Page 2: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/2.jpg)
Learning outcomes
The student will be able to:
• List the types of enzyme inhibitors
• Describe the mechanism of enzyme catalysis and drug resistance
• Discuss and apply theory of drug synergism
• Discuss mechanism of action of reversible and irreversible enzyme inhibitors
• Describe rational design of enzyme inhibitors
![Page 3: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/3.jpg)
Types of enzyme inhibitors
• Reversible inhibitors – involve reversible inhibition of enzyme via non-covalent interactions
• Irreversible inhibitor (Enzyme inactivator) - inhibits enzyme for an extended period of time via covalent interactions
![Page 4: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/4.jpg)
Reversible Enzyme Inhibitors
1. Competitive inhibitors - compete with substrate for active site (structures similar to substrates or products)
a) Simple competitive inhibitors
b) Alternative substrate inhibitors
c) Transition state analogs
d) Slow, tight-binding inhibitors
2. Noncompetitive inhibitors - bind to a site other than active site (an allosteric site)
![Page 5: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/5.jpg)
Mechanism of reversible inhibition
E + PE•PE•S
-S +S
E•I
koff
kon
E + I
• EI concentration depends on [I] and [S] and their dissociation constants (Ki and Km, respectively).
• Both S and I compete for E, (so a decrease in [I] or increase in [S], will decrease the [EI] and increases[ES]).
![Page 6: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/6.jpg)
a) Simple Competitive Reversible Inhibitors
• E.g. antihypertensive drugs: ACE inhibitors - Captopril, enalapril, and lisinopril
• Hypertensive Effects of ACE
• Produces angiotensin II, a vasoconstrictor, also trigger release of a hormone, aldosterone that regulates the electrolyte balance by retention of Na+ and water.
• Angiotensin II is converted to angiotensin III, which also releases aldosterone.
• ACE also catalyzes hydrolysis of a vasodilator, bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg)
Hypertensive Effects of ACE
May be involved in memory retention & neuronal development
![Page 7: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/7.jpg)
Lead Discovery
• 1965 - mixture of peptides in the venom of a South American pit viper shows inhibition of bradykininase activity and inhibits conversion of angiotensin I to angiotensin II Teprotide (Pyr-Trp-Pro-Arg-Pro –Gln-Ile-Pro-Pro)
– showed highest activity in vivo
![Page 8: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/8.jpg)
Lead Modification
• Testing peptides inhibitors on ACE showed that:
– Pro is best at C-terminal, Ala at penultimate and an aromatic residue at antepenultimate position.
• ACE was found to contain Zn2+ that was believed to assist hydrolysis as a cofactor
ACE catalytic site was assumed to resemble carboxypeptidase A
![Page 9: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/9.jpg)
• With (R)-2-benzylsuccinic acid as a model, a series of peptidomimetic, carboxyalkanoylproline derivatives (e.g. 1) were tested as inhibitors of ACE.
– All were only weak inhibitors of ACE.
• To increase potency, COO- was changed to SH that coordinate better to Zn(II).
Lead Modification
![Page 10: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/10.jpg)
Hypothetical binding of inhibitors to ACE
Carboxylate analog
Thiol analog
Note: Active site of ACE has two additional binding site than carboxypeptidase
![Page 11: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/11.jpg)
Effect of Structural Modifications
• Captopril had the best binding properties (Ki = 1.7 nM), It was also highly selective for ACE
• SAR studies showed that every part of captopril is important for binding.
(captopril)
Analog Relative Ki
1.0
12,500
10
12,000
120
120
1,100
CO2H
HS N
O
H3 C H
HH3 C
O
NHS
CO2H
HS N
O
HS
O
N
CO2H
CO2HHS
HN
O
CH3H
O
NHS
CO2H
CO2H
HOOC N
O
H3 C HCaptopril was the first ACE inhibitor on the drug market - hypertension and congestive heart failure.
![Page 12: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/12.jpg)
• Captopril showed two reversible side effects (rashes and loss of taste) - Merck hypothesized side effects
from SH group.
A lipophilic group was added to reduce hydrophilicity and also to increase binding to S1 sub-site on ACE
Changed SH back to COO-
CH2 replaced by NH to increase interaction with enzyme,
– gave less potent molecule due to high hydrophilicity
enalaprilat: R = (S)-PhCH2CH2, R’ = H was the best candidate
enalaprilat was poorly absorbed orally - remedied by enalapril, an ethyl ester which is hydrolyzed in vivo by esterases to give enalaprilat
![Page 13: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/13.jpg)
lisinopril5.29
CH2
CH2CO2H
H NH
N
H(CH2)4
CO2HO
NH2
Does not require prodrug activation.
![Page 14: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/14.jpg)
b) Competitive Reversible Inhibitor that Acts as Substrate
• Examples are Sulfonamide Antibacterial Agents (Sulfa Drugs)
Lead discovery
• Bayer Co. tested azo dyes against streptococci. Prontosil was very effective in mice (1935).
• No activity in vitro unless a reducing agent is added.
• In vivo protonsil is metabolized by reduction to the active agent – it is a prodrug.
• the active agent is the bacteriostatic sulfanilamide
bacteriostatic - inhibits further growth of bacteria, but does not kill them.
![Page 15: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/15.jpg)
Lead Modification
• Prontosil - beginning of modern chemotherapy
• Thousands of compounds synthesized and tested - the first SAR studies
• 1st example where new leads for other diseases discovered from side effects in clinical studies - antidiabetic and diuretic agents
Other developments from these studies:
• a simple assay for these compounds in body fluids
• showed antibacterial effect is proportional to the concentration in blood, which varied from patient to patient at a given dose - beginning of monitoring blood drug levels during chemotherapy
![Page 16: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/16.jpg)
Mechanism of Action • In 1939 Stamp showed microorganisms contained a substance that
blocked the antibacterial action of sulfonamides
• In 1940 Woods hypothesized that this substance has structure similar to the enzyme substrate
• He also showed that it is p-aminobenzoic acid (PABA) and it compete with sulfanilamide for microbial growth
• Mid 1940s - Miller shows sulfanilamide inhibits folic acid biosynthesis
• Sulfonamides were shown to
be substrates for
Dihydropteroate synthase
• 1969 - Richey and Brown purified two enzymes involved in biosynthesis of dihydrofolate
(inhibiting formation of dihydrofolate needed for purines and DNA biosynthesis in bacteria)
![Page 17: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/17.jpg)
Criteria for a good antimicrobial drug target
1. Target is essential to survival of microorganism
2. Target is unique to the microbe so humans are not harmed
3. Structure and function of the target is highly conserved across a variety of species of that microbe for broad spectrum
4. Resistance to inhibitors of target not easily acquired
• Dihydropteroate synthase satisfies the first 3 criteria – It generally takes 1-4 years for resistance to emerge;
resistance to sulfonamides took almost seven years.
![Page 18: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/18.jpg)
Sulfonamides- Drug Resistance
• Overproduction of PABA
• Formation of a dihydropteroate synthase that binds PABA normally, but binds sulfonamides thousands of times less tightly
• Altered permeability of sulfonamides
![Page 19: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/19.jpg)
c) Transition State Analogs
• Bernhard and Orgel – theorized that:
– inhibitor molecules resembling transition state structure are more tightly bound to enzyme than substrate
![Page 20: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/20.jpg)
Pentostatin – an example of transition state analogs
2-deoxyinosine
2-deoxyadenosine
pentostatin5.58
HN
NN
N
HO H
OHO
OH
Antineoplastic agent isolated from bacterium Streptomyces antibioticus
A potent inhibitor of
adenosine deaminase Ki =
2.5 x 10-12 M (2.5
pM)(107 times lower than Km
for adenosine!)
pentostatin mimics this
![Page 21: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/21.jpg)
Multisubstrate transition state analog
• When more than one substrate is involved, a single stable compound is made with a structure similar to the two or more substrates at the transition state - multisubstrate analog inhibitor.
![Page 22: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/22.jpg)
‡
..
5.67
5.66
O
O
NH2
PO3=
NH2
COO-
H
COO-
COO-
H
COO-
NH2
O
PO3=
NH2
O
COO-
H
COO-
NH
NH2
O
NH
O
CH2
PO3=
COO-
H
COO-
5.65
N-Phosphonoacetyl-L-Asp (PALA) an example of Multisubstrate Analog
Aspartate transcarbamylase – catalyze de novo biosynthesis of pyrimidines from carbamoyl phosphate and L- Asp PALA resembles the transition state
carbamoyl phosphate
isostere - no longer a leaving group, mimics phosphate
N-carbamoyl-L-Asp
PALA
PALA was inffetctive due to tumor resistance: •tumor cells acquired ability to utilize preformed circulating pyrimidine nucleosides • increased carbamoyl phosphate • increased aspartate transcarbamylase
![Page 23: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/23.jpg)
Slow, Tight-Binding Inhibitors
• Slow-binding inhibitors - equilibrium between enzyme and inhibitor is reached slowly (kon small); inhibition is therefore time-dependent
• Tight-binding inhibitors - substantial inhibition when [E] and [I] are comparable (koff small)
• Slow, tight-binding inhibitors – have both properties t1/2 for EI complex can be up to months
![Page 24: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/24.jpg)
Slow, Tight-Binding Inhibitors – Examples • Examples of Slow, Tight-Binding Inhibitors the Antihypercholesterolemic
drugs Lovastatin and Simvastatin
• About 1/2 of body cholesterol is biosynthesized; the rest needs to be eaten. Some people biosynthesize much more than half of what they need.
• Rate-determining step in cholesterol biosynthesis is conversion of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to mevalonic acid.
• Inhibition of HMG-CoA reductase should lower plasma cholesterol levels.
5.70
HMG-CoA reductase
2 NADP+2 NADPH
5.695.68
NADP+
NADPH-CoASH
NADP+
NADPH
O
H3 C
COOHHO
SCoA
OH
HO COOH
H3 C
O
H3 C
COOHHO
SCoA H
HO COOH
H3 C
OH
H:B
HMG-CoA
Mevalonic acid
![Page 25: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/25.jpg)
O
CH2 C
CH3
CH3
CH
OH
C
O
NHCH2CH2 CNHCH2CH2 S
O
PO O-
O
PO O CH2
O- O
=O3PO OH
N
N
N
N
NH2
O
COOHHO
H3 C
CoA
HMG-CoA
![Page 26: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/26.jpg)
mevastatin or compactin (R = H)
monacolin K, mevinolin, or lovastatin (R = CH3)5.71
CH3
O
O
H3C H
R
H
HO O
O
Lead Discovery • Endo and coworkers
(Sankyo Co. in Japan) found three compounds from fungus Penicillium citrinum that inhibited sterol biosynthesis – mevastatin was most potent.
• A more potent compound was isolated by Endo from a different fungus - called monacolin K.
• Mechanism of Action: Potent competitive reversible inhibitors of HMG-CoA reductase (Ki for lovastatin 6.4 x 10-10 M)
![Page 27: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/27.jpg)
• The active form of lovastatin is the hydrolysis product.
• This mimics intermediate 5.70 in Scheme 5.10.
Active form of lovastatin
when H is replaced by CH3, it is simvastatin (2.5 times more potent than lovastatin)
5.70
O
H3C
COOHHO
SCoA
H
H:B
5.73
3
5
CH3
OH
H
COOH
O
H3C H
CH3
H
HOH
O
![Page 28: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/28.jpg)
Irreversible Enzyme Inhibitors
• Two general types of irreversible inhibitors:
– Affinity labeling agents (reactive compounds)
– Mechanism-based enzyme inactivators (unreactive compounds)
Note: Irreversible inhibition does not mean permanent loss of the enzyme - gene encodes for other copies (may take hours or days).
![Page 29: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/29.jpg)
Affinity Labeling Agents
• These are reactive compounds that have structure similar to that of substrate of the target enzyme
covalent complex
SN2 alkylation or acylation
reversible complex
Effective Affinity Labeling Agents have:
• low Ki for target enzyme for selectivity
• reactive group close to a nucleophile in active site of target enzyme
![Page 30: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/30.jpg)
-lactam antibiotics – Examples affinity labeling agents
![Page 31: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/31.jpg)
-lactam antibiotics inactivate Peptidoglycan transpeptidase which catalyze the cross-linking of peptidoglycan to form bacteria cell wall
OOHO
OH
NHAc
OO
OH
O
NHAcO
HH3 C
O
O
HO
OH
NHAc
O
GlcNAc MurNAc GlcNAc
-
L-Ala
D--Glu
Lys-NH2
NH
CHCH3
NH
CHCH3
COO
L
(D)
(D)
+
O
BH
H
B:
peptidoglycan transpeptidase
D-Ala
C O
GlcNAc MurNAc GlcNAc
OH
H3 CO
L-Ala
D--Glu
Lys-NH2
NH
CHCH3
O
L
(D)
C O
Ser
GlcNAc MurNAc GlcNAc
O
O
H
CH3
D-Ala
D-Ala
Lys
D--Glu
L-Ala
L NH2
GlcNAc MurNAc GlcNAc
OH
H3 CO
L-Ala
D--Glu
Lys-NH2
NH
CHCH3
L
(D)
C O
GlcNAc MurNAc GlcNAc
O
O
H
CH3
D-Ala
D-Ala
Lys
D--Glu
L-Ala
L NH
5.10
![Page 32: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/32.jpg)
Penicillin inactivate the enzyme by acylating serine at active site
H
N b
N b
MeN a
Me
H
H
CO2H
O
Peptidoglycan
SN a
H H
CO2H
Me
Me
O
R
O
O
H
H
H
The structure of penicillin is comparable with D-Ala-D-Ala which is hydrolyzed by the enzyme
![Page 33: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/33.jpg)
Penicillin Resistance: Occurs via 1. -Lactamase production - hydrolyzes -lactam ring 2. Also, transpeptidase becomes less susceptible to acylation. 3. Membrane permeability is modified.
Drug Synergism: combination therapy (penicillin + -lactamase inhibitor) e.g. • Augmentin (amoxicillin + clavulanate) • Unasyn (ampicillin + sulbactam)
clavulanate potassium5.92
N
O
O
OH
CO2-K+
sulbactam5.93
N
S
O
OO
CO2H
![Page 34: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/34.jpg)
Mechanism-Based Enzyme Inactivators
• is an unreactive molecule with structure
similar to substrate or product
• once bound the target enzyme converts it
into a species that inactivates the enzyme
Their differences from affinity labeling agents are
• initially unreactive
• target enzyme activates them by catalysis
![Page 35: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/35.jpg)
Mechanism-Based Inactivation Kinetics
E + I E • I E • I '
E + P
E - I ' '
k1
k-1
k2 k4
k3
partition ratio = k3/k4
ideally, partition ratio = 0
• Note: Inactivation occurs prior to release of the activated species
![Page 36: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/36.jpg)
Vigabatrin – Examples of Mechanism-Based Inactivation
• Vigabatrin is an antiepileptic drug • Epilepsy - Can arise from imbalance in two neurotransmitters (L-Glu
and GABA)
• Thus an alternative to treat epilepsy could be introduce GABA into brain
• However, GABA does not cross blood-brain barrier
• Vigabatrin crosses blood-brain barrier, and inactivates GABA aminotransferase via mechanism-based inactivation.
- -
--+
-+GADPLP-CO2
GABA-AT
PLP PMP
-KGL-GluSSADH
NADP+
NADPH
H3N CO2
CO2
H3N CO2OHC
CO2
O2 CCO2
-
![Page 37: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/37.jpg)
• Vigabatrin can cross the BBB because vinyl group: – increases lipophilicity of the compound – is electron withdrawing it will lower pKa of
the amino group thus increasing the nonzwitterionic form
![Page 38: Drug Discovery through Enzyme Inhibition and …...tested - the first SAR studies • 1st example where new leads for other diseases discovered from side effects in clinical studies](https://reader035.vdocument.in/reader035/viewer/2022070620/5e2ee589782c0857901cdcaa/html5/thumbnails/38.jpg)
Mechanism of action of Vigabatrin
1
2
3
4 5